- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| Mi | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Reviva Pharmaceuticals GAAP EPS of -$0.19 beats by $0.17 | 2 | Seeking Alpha | ||
| Mi | Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 131 | GlobeNewswire (Europe) | - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback... ► Artikel lesen | |
| 10.07. | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 6 | SEC Filings | ||
| 13.05. | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 4 | Seeking Alpha | ||
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 408 | GlobeNewswire (Europe) | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| 13.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 624 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 389 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 218 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,790 | -0,56 % | $600 Milliarden Kredite: Krise am US-Agrarmarkt weitet sich aus, Banken werden nervös | © Foto: wO-ChatGPT Amerikas Farmer kämpfen mit sinkenden Einnahmen und steigenden Kosten. Nun verschärfen Kreditgeber ihre Kontrollen. Der Agrarkreditmarkt sendet ein deutliches Warnsignal.Auf den Feldern... ► Artikel lesen | |
| NOVO NORDISK | 39,405 | -2,58 % | Milliarden-Innovationen und Übernahmekandidaten: Warum Eli Lilly, GSK und Johnson & Johnson jetzt auf Einkaufstour gehen | ||
| ROCHE | 377,19 | -2,65 % | Aktien Europa: Weiter hoch - Markt wartet auf US-Arbeitmarktbericht | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die europäischen Aktienmärkte haben am Freitag ihre Aufwärtsbewegung in kleinen Schritten fortgesetzt. Die aktuelle Entwicklung steht allerdings unter Vorbehalt. "Heute... ► Artikel lesen | |
| VIATRIS | 13,994 | +0,55 % | Viatris raises 2026 outlook while targeting $500M peak sales for fast-acting meloxicam | ||
| GREEN THUMB INDUSTRIES | 6,310 | -0,63 % | Green Thumb Industries Inc: Green Thumb opens RISE dispensary in Florida | ||
| QUANTUM BIOPHARMA | 3,008 | +4,81 % | Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial | TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 64,06 | -2,79 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 13,400 | -2,90 % | EQS-DD: Newron Pharmaceuticals S.p.A.: Prisca Anand, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
12.08.2026 / 16:35... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,806 | -1,59 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,740 | -1,32 % | ORAMED PHARMACEUTICALS INC. - 10-Q, Quarterly Report | ||
| COMPASS PATHWAYS | 11,500 | -0,86 % | Warum Lillys 3,8-Milliarden-Dollar-Deal den Psychedelika-Sektor verändert - und warum Emyria jetzt in den Fokus rücken könnte | ||
| ACHIEVE LIFE SCIENCES | 5,700 | -9,52 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| OPKO HEALTH | 1,200 | +0,84 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| OPUS GENETICS | 3,260 | +0,62 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update | OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,255 | +0,65 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,20 %) liegt der Kurs bei 0,351 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.